...SOM said that in November it granted an undisclosed company worldwide rights to tolcapone (SOM0226). The...
...amyloidosis. SOM declined to disclose additional details. SOM Biotech S.L. , Barcelona, Spain Business: Endocrine/Metabolic Alicia Parker SOM0226 Tolcapone SOM...

...CNS. Next steps include further optimization of the compounds. Roche markets the COMT inhibitor Tasmar tolcapone...

...that inhibited the activity of human COMT with greater potency than the COMT inhibitors Tasmar tolcapone...

...antisense inhibitor Ph II/III for FAP mNIS+7 and Norfolk QOL questionnaire SOM Biotech S.L. Tolcapone (SOM0226...

...doses of 200 mg oral SOM0226 and up to 3 doses of 100 mg oral SOM0226...
...Hereditary ATTR amyloidosis meeting in Paris. SOM Biotech S.L. , Barcelona, Spain Product: Tolcapone ( SOM0226...

...Biotech's SOM0226 tolcapone showed stabilization of plasmatic TTR in all 21 patients receiving the therapy. SOM0226...
...is a stabilizer of tetrameric TTR and a TTR fibril disruptor. Roche (SIX:ROG; OTCQX:RHHBY) markets tolcapone...

...the North American market. The deal includes Valeant’s Mestinon pyridostigmine to treat myasthenia gravis; Tasmar tolcapone...

...is the North American market. The deal includes Mestinon pyridostigmine to treat myasthenia gravis; Tasmar tolcapone...

...Xyrem, which is approved in Canada, to launch mid-year. VRX markets Zelapar selegiline and Tasmar tolcapone...

...female patients with altered activity of the enzyme. Unfortunately, the only marketed COMT inhibitor, Tasmar tolcapone...